Phase 3 Study of 5-ALA in Meningioma Surgery Meets Primary Endpoint

photonamic GmbH & Co KG (Photonamic) are pleased to announce that our U.S. subsidiary, NX Development Corporation (NXDC), has successfully completed its phase 3 study (MEN-301) and comfortably met the primary endpoint, investigating 5-ALA as an adjunct in meningioma patients undergoing fluorescence-guided surgery. Read Full Press Release

The release as fetched from its publisher. photonamic.de ↗